Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -20.00p -5.06% 375.00p 370.00p 380.00p 395.00p 375.00p 395.00p 76,571 14:27:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 67.2 13.9 14.2 26.4 251.70

Eco Animal Health Share Discussion Threads

Showing 576 to 599 of 1025 messages
Chat Pages: Latest  29  28  27  26  25  24  23  22  21  20  19  18  Older
DateSubjectAuthorDiscuss
01/4/2016
13:30
dont you run your winners..........look at buffett. eah has big barriers to entry
smelleroo
01/4/2016
10:54
AuDigger - yes that's my view too.
aimingupward2
01/4/2016
10:02
I'm in two minds about whether to hold in the anticipation the PL sells the company as he executes his exit plan or whether to sell now and take a handsome profit. I bought mine at prices ranging from 140-220 so am sitting on a good return. However, as revenue/profit continues to grow the divi should continue to increase so these are OK from an income perspective and any take out is likely to be at a significant premium to the current share price ....400-500 is my guess. On balance I think I'll hold. What ever happened to ITinvest? Or is topvest a re-branded version of IT?....I say that based on on similarity of the name.
audigger
01/4/2016
09:01
topvest, when you say "our patience will be rewarded", what are your expectations? The share price is already on a pretty high p.e. ratio, so might it not be more a case of future earnings catching up with the share price rather than the other way round? I do appreciate, though, that a buy-out might well be at a higher rating as a company with it's own sales force(s) would make higher margins than EAH is currently able to do using sales agents - is that your main driver of hope?
aimingupward2
31/3/2016
20:09
And so only two posts today! This isn't on anyone's radar. This business is in great shape and growing well in different geographies. Also the business benefits from strong US dollar. We surely have to be catching the eye of some people or should that be companies ;)
smelleroo
31/3/2016
20:03
All shaping up nicely for ECO. Our patience will be rewarded min my view. Just a matter of waiting for value to crystallise.
topvest
31/3/2016
08:45
Nice to see the share price jump on this news. Was doing some digging on the technical profile of Aivlosin and I was surprised to see that it isn't approved for use on egg laying hens in the EU. If they manage to generate the data to support this approval then there will be much more upside to the EU business in addition to the huge opportunity in the US. It was interesting to see that FDA allowed a zero day withholding period as Eco tried to get this in Europe but it wasn't approved. Theoretically the FDA allowing this jay give Eco some leverage to re-state their case for having the same in Europe
audigger
31/3/2016
07:19
bullish update....... Peter Lawrence, Chairman of ECO commented “We are delighted to receive this marketing authorisation in the United States. This key milestone follows many years of investment in product development and regulatory activity in North America. The USA represents more than one third of the world market for our products and this breakthrough will benefit our future profitable growth. It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products”.
smelleroo
25/2/2016
13:50
Pill-Popping Pigs Put Humans at Risk of Disease: Editorial 2016-02-25 13:00:34.313 GMT By The Editors (Bloomberg View) -- If humans take too many antibiotics -- and they do -- then the animals they eat take even more. Learning more about how and why farmers use so many drugs is crucial to arresting the speed at which bacteria are developing immunity to them. This immunity is a major global threat to public health. Antibiotic-resistant infections kill 23,000 people each year in the U.S. alone and cost $55 billion in medical treatment and lost work days. So President Barack Obama’s 2017 budget contains money to pay for better data on the scope of antibiotic use in farm animals. Congress, which has dropped such funding in the past, needs to see that this time it gets through. The use of antibiotics in agriculture is on the rise: Since 2009, when the Food and Drug Administration began measuring antibiotics given to food animals, use has risen 22 percent. The drugs are typically delivered in feed and water to prevent disease in cattle, pigs, chickens and turkeys and to help them grow. As bacteria that infect farm animals become immune to the drugs, they threaten to jump off the farm and into the human population, as has happened with avian flu in Asia. Unfortunately, that increase, derived from the drug makers’ sales figures, is essentially all that’s known about the scope of antibiotic use in food animals. Farms supply no usage statistics, so it’s impossible to know how much of each drug is given to each type of animal, and at what ages; whether the drugs have been prescribed for an actual illness, as a prophylactic against common diseases, or simply to increase growth; and how exactly they’re administered. Obama’s budget proposes to increase USDA spending to $61 million to help collect the missing data. The bad news is that in last year’s budget proposal, the president allocated $77 million for such research, but when the final omnibus budget deal materialized at the end of 2015, that money was nowhere to be found. Public health experts fear the disappearing act will be repeated once Congress, a strong ally of farm and pharmaceutical interests, makes final appropriations. This would be doubly unfortunate, as a better data- collection regime could build on improved Food and Drug Administration regulations that, by the end of this year, will end the agricultural use of antibiotics for growth enhancement alone, require stronger oversight of diseased animals by veterinarians, and improve record-keeping. Some of biggest producers and retailers in the U.S., including Perdue and Wal-Mart, have demonstrated a real desire to reduce their dependence on antibiotics. They could work with government scientists in a public-private effort to help growers change their animals’ diets and living conditions so as to raise healthy and robust livestock with fewer drugs. A similar compromise had great success in Denmark, a major pork exporter. To create a better system, however, we first need far more detailed information about how antibiotics are being used on the farm.
smelleroo
24/2/2016
07:51
All quiet on the Eco front. Next landmark will be the results unless we get a "profit to be above expectations" RNS in the meantime. With the weakness of the pound and the growth in USD sales things should be looking good. And with consolidation in the chemicals industry all the rage, it may be take over time!
audigger
21/1/2016
12:16
As there is high proportion of overseas earnings, the recent weakness of the £ will translate into probably higher sterling profits than forecast.
aimingupward2
07/1/2016
16:54
Gently does it.
audigger
04/1/2016
12:58
Good start to the year as we achieve new highs. I think this is the year that EAH may be bought out hopefully on the back of more record breaking results come May.
audigger
22/12/2015
09:00
Just won't go away.......... hxxp://www.expressandstar.com/news/uk-news/2015/12/21/gene-making-superbug-bacteria-resistant-to-last-resort-antibiotic-found-in-uk/
smelleroo
16/12/2015
21:31
I didn't see the second rns....he'll be seriously wealthy when he sells out. Lots of consolidation going on in the chemical industry so the time may be ripe for Eco to be acquired by one of the big boys.
audigger
16/12/2015
08:03
Peter Lawrence buying a few more at 310p!
smelleroo
15/12/2015
10:10
Directors taking some profits for Christmas!
audigger
10/12/2015
10:31
EAH reported eps of 6.8p for the year ended March '15, so why is the IC saying they reported 11.8p?
aimingupward2
09/12/2015
15:57
A major concern in healthcare is that the prolific use of antibiotics in food production makes the bacteria that infect humans more resistant. This is helpful for Eco Animal Health (EAH), whose Aivlosin product contains the antibiotic tylvalosin and treats respiratory and intestinal diseases in pigs and poultry. Demand is soaring for the drug because its low dosage rate and ability to move quickly through the animals' systems - before the meat enters the food chain - allays fears about microbial resistance. First-half sales of Aivlosin grew 32 per cent, with strong performances in all major territories. In North America, one of Eco's major markets, even mild weather and low disease rates couldn't stop Aivlosin sales rising 16 per cent. This helped push global sales of all products up 28 per cent at constant currencies. Adjusted cash profit rose 36 per cent on the same basis to £4.3m, paving the way for a big increase in the dividend. Analysts at Peel Hunt expect pre-tax profit of £9.6m for the year ending March 2016, giving EPS of 12.1p, compared with £8.2m and 11.8p in FY2015. ECO ANIMAL HEALTH (EAH) ORD PRICE: 318p MARKET VALUE: £203m TOUCH: 310-325p 12-MONTH HIGH: 320p LOW: 191p DIVIDEND YIELD: 1.6% PE RATIO: 41 NET ASSET VALUE: 125p* NET CASH: £17m Half-year to 30 Sep Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2014 17.0 2.0 2.7 1.5 2015 21.5 2.7 3.5 1.9 % change +27 +33 +31 +27 Ex-div: 10 Mar Payment: 4 Apr *Includes intangible assets of £47.2m, or 74p a share IC VIEW: Shares in Eco Animal Health are up 64 per cent over the past 12 months as a strong financial performance has been cemented by analyst upgrades. That's left them trading on 26 times forward earnings, which fairly reflects the significant growth opportunity presented by the responsible use of antimicrobial products. Hold. Last IC view: Hold, 300p, 6 Jul 2015 visible-status-Standard story-url-Eco Animal Health HY results 8 12 15.xml
smelleroo
08/12/2015
08:46
A lot of people banging on about a theoretical risk often so they can secure funding for their own research. However, if one considers the very real threat of superbugs in hospitals and the vast number of deaths they cause every year, then I think the animal health issue pales in to insignificance. Sort out the hospitals first then worry about funding your own research later! In the meantime, enjoy your rare steaks. Next stop director buys!
audigger
08/12/2015
08:35
Rare steaks 'could put diners at risk of superbugs' The head of a major Government review warns that consumers could contract superbugs from eating rare and undercooked meats, because of the rise of antibiotic use among animals http://www.telegraph.co.uk/news/health/news/12038056/Rare-steaks-could-put-diners-at-risk-of-superbugs.html
smelleroo
07/12/2015
19:24
They command a high valuation I believe as any acquirer could drastically reduce costs through using their own distribution network. Anyone done any work on this?
topvest
07/12/2015
08:05
Yes, these were good. Definitely a growth stock at last. It's been a long wait.
topvest
07/12/2015
07:30
indeed, very!
smelleroo
Chat Pages: Latest  29  28  27  26  25  24  23  22  21  20  19  18  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190520 15:22:06